(IQV) IQVIA Holdings - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US46266C1053
Stock: Clinical Research, Analytics, Consulting, Trial Support, Outsourcing
Total Rating 34
Risk 64
Buy Signal -0.35
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 93.3% |
| Relative Tail Risk | -9.48% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.17 |
| Alpha | -25.69 |
| Character TTM | |
|---|---|
| Beta | 1.114 |
| Beta Downside | 1.155 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.12% |
| CAGR/Max DD | -0.12 |
Description: IQV IQVIA Holdings December 17, 2025
IQVIA Holdings Inc. (NYSE:IQV) delivers end-to-end data, analytics, and clinical services to life-science and health-care companies across the Americas, Europe, Africa, and Asia-Pacific, organized into three operating segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Key recent metrics: FY 2023 revenue reached $13.1 billion, up 5 % YoY, driven by a 12 % rise in the Real-World Evidence (RWE) platform and a 9 % increase in contract sales services. The company posted an adjusted operating margin of 13.2 % and generated $1.8 billion of free cash flow, supporting its $2.5 billion backlog of multi-year contracts. Core sector drivers include accelerating pharmaceutical R&D spend (projected CAGR ≈ 7 % through 2028), the industry’s shift toward decentralized clinical trials, and heightened regulator demand for real-world data to inform drug approvals.
For deeper valuation metrics and scenario analysis, you might find ValueRay’s IQV page worth a look.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 1.47b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.54 > 1.0 |
| NWC/Revenue: -12.92% < 20% (prev -8.88%; Δ -4.04% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.63b > Net Income 1.47b |
| Net Debt (14.19b) to EBITDA (3.60b): 3.94 < 3 |
| Current Ratio: 0.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (171.9m) vs 12m ago -6.68% < -2% |
| Gross Margin: 26.54% > 18% (prev 0.33%; Δ 2621 % > 0.5%) |
| Asset Turnover: 56.61% > 50% (prev 56.35%; Δ 0.26% > 0%) |
| Interest Coverage Ratio: 3.43 > 6 (EBITDA TTM 3.60b / Interest Expense TTM 711.0m) |
Altman Z'' 1.73
| A: -0.07 (Total Current Assets 6.25b - Total Current Liabilities 8.34b) / Total Assets 29.94b |
| B: 0.25 (Retained Earnings 7.42b / Total Assets 29.94b) |
| C: 0.09 (EBIT TTM 2.44b / Avg Total Assets 28.56b) |
| D: 0.77 (Book Value of Equity 17.86b / Total Liabilities 23.31b) |
| Altman-Z'' Score: 1.73 = BBB |
Beneish M -2.79
| DSRI: 1.00 (Receivables 3.43b/3.25b, Revenue 16.17b/15.31b) |
| GMI: 1.26 (GM 26.54% / 33.42%) |
| AQI: 1.00 (AQ_t 0.76 / AQ_t-1 0.76) |
| SGI: 1.06 (Revenue 16.17b / 15.31b) |
| TATA: -0.04 (NI 1.47b - CFO 2.63b) / TA 29.94b) |
| Beneish M-Score: -2.79 (Cap -4..+1) = A |
What is the price of IQV shares?
As of February 09, 2026, the stock is trading at USD 187.49 with a total of 3,443,048 shares traded.
Over the past week, the price has changed by -18.92%, over one month by -22.90%, over three months by -12.00% and over the past year by -9.41%.
Over the past week, the price has changed by -18.92%, over one month by -22.90%, over three months by -12.00% and over the past year by -9.41%.
Is IQV a buy, sell or hold?
IQVIA Holdings has received a consensus analysts rating of 4.30.
Therefore, it is recommended to buy IQV.
- StrongBuy: 14
- Buy: 2
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IQV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 247.4 | 31.9% |
| Analysts Target Price | 247.4 | 31.9% |
| ValueRay Target Price | 181.7 | -3.1% |
IQV Fundamental Data Overview February 08, 2026
P/E Trailing = 23.9145
P/E Forward = 13.8122
P/S = 1.9577
P/B = 4.7195
P/EG = 0.7674
Revenue TTM = 16.17b USD
EBIT TTM = 2.44b USD
EBITDA TTM = 3.60b USD
Long Term Debt = 12.79b USD (from longTermDebt, last quarter)
Short Term Debt = 1.84b USD (from shortTermDebt, last quarter)
Debt = 16.17b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.19b USD (from netDebt column, last quarter)
Enterprise Value = 46.29b USD (31.93b + Debt 16.17b - CCE 1.81b)
Interest Coverage Ratio = 3.43 (Ebit TTM 2.44b / Interest Expense TTM 711.0m)
EV/FCF = 23.14x (Enterprise Value 46.29b / FCF TTM 2.00b)
FCF Yield = 4.32% (FCF TTM 2.00b / Enterprise Value 46.29b)
FCF Margin = 12.37% (FCF TTM 2.00b / Revenue TTM 16.17b)
Net Margin = 9.07% (Net Income TTM 1.47b / Revenue TTM 16.17b)
Gross Margin = 26.54% ((Revenue TTM 16.17b - Cost of Revenue TTM 11.88b) / Revenue TTM)
Gross Margin QoQ = 6.69% (prev 32.94%)
Tobins Q-Ratio = 1.55 (Enterprise Value 46.29b / Total Assets 29.94b)
Interest Expense / Debt = 1.19% (Interest Expense 193.0m / Debt 16.17b)
Taxrate = 10.14% (58.0m / 572.0m)
NOPAT = 2.19b (EBIT 2.44b * (1 - 10.14%))
Current Ratio = 0.75 (Total Current Assets 6.25b / Total Current Liabilities 8.34b)
Debt / Equity = 2.49 (Debt 16.17b / totalStockholderEquity, last quarter 6.50b)
Debt / EBITDA = 3.94 (Net Debt 14.19b / EBITDA 3.60b)
Debt / FCF = 7.10 (Net Debt 14.19b / FCF TTM 2.00b)
Total Stockholder Equity = 6.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.13% (Net Income 1.47b / Total Assets 29.94b)
RoE = 24.11% (Net Income TTM 1.47b / Total Stockholder Equity 6.08b)
RoCE = 12.92% (EBIT 2.44b / Capital Employed (Equity 6.08b + L.T.Debt 12.79b))
RoIC = 10.59% (NOPAT 2.19b / Invested Capital 20.69b)
WACC = 7.01% (E(31.93b)/V(48.10b) * Re(10.02%) + D(16.17b)/V(48.10b) * Rd(1.19%) * (1-Tc(0.10)))
Discount Rate = 10.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.28%
[DCF Debug] Terminal Value 82.40% ; FCFF base≈1.98b ; Y1≈2.07b ; Y5≈2.40b
Fair Price DCF = 222.4 (EV 51.92b - Net Debt 14.19b = Equity 37.73b / Shares 169.6m; r=7.01% [WACC]; 5y FCF grow 4.84% → 2.90% )
EPS Correlation: -11.40 | EPS CAGR: 9.07% | SUE: 0.10 | # QB: 0
Revenue Correlation: 88.66 | Revenue CAGR: 5.92% | SUE: 1.44 | # QB: 3
EPS next Quarter (2026-03-31): EPS=2.83 | Chg30d=-0.123 | Revisions Net=+1 | Analysts=14
EPS current Year (2026-12-31): EPS=12.69 | Chg30d=-0.256 | Revisions Net=+0 | Growth EPS=+6.4% | Growth Revenue=+5.5%
EPS next Year (2027-12-31): EPS=14.13 | Chg30d=-0.186 | Revisions Net=-2 | Growth EPS=+11.4% | Growth Revenue=+5.9%
P/E Forward = 13.8122
P/S = 1.9577
P/B = 4.7195
P/EG = 0.7674
Revenue TTM = 16.17b USD
EBIT TTM = 2.44b USD
EBITDA TTM = 3.60b USD
Long Term Debt = 12.79b USD (from longTermDebt, last quarter)
Short Term Debt = 1.84b USD (from shortTermDebt, last quarter)
Debt = 16.17b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 14.19b USD (from netDebt column, last quarter)
Enterprise Value = 46.29b USD (31.93b + Debt 16.17b - CCE 1.81b)
Interest Coverage Ratio = 3.43 (Ebit TTM 2.44b / Interest Expense TTM 711.0m)
EV/FCF = 23.14x (Enterprise Value 46.29b / FCF TTM 2.00b)
FCF Yield = 4.32% (FCF TTM 2.00b / Enterprise Value 46.29b)
FCF Margin = 12.37% (FCF TTM 2.00b / Revenue TTM 16.17b)
Net Margin = 9.07% (Net Income TTM 1.47b / Revenue TTM 16.17b)
Gross Margin = 26.54% ((Revenue TTM 16.17b - Cost of Revenue TTM 11.88b) / Revenue TTM)
Gross Margin QoQ = 6.69% (prev 32.94%)
Tobins Q-Ratio = 1.55 (Enterprise Value 46.29b / Total Assets 29.94b)
Interest Expense / Debt = 1.19% (Interest Expense 193.0m / Debt 16.17b)
Taxrate = 10.14% (58.0m / 572.0m)
NOPAT = 2.19b (EBIT 2.44b * (1 - 10.14%))
Current Ratio = 0.75 (Total Current Assets 6.25b / Total Current Liabilities 8.34b)
Debt / Equity = 2.49 (Debt 16.17b / totalStockholderEquity, last quarter 6.50b)
Debt / EBITDA = 3.94 (Net Debt 14.19b / EBITDA 3.60b)
Debt / FCF = 7.10 (Net Debt 14.19b / FCF TTM 2.00b)
Total Stockholder Equity = 6.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.13% (Net Income 1.47b / Total Assets 29.94b)
RoE = 24.11% (Net Income TTM 1.47b / Total Stockholder Equity 6.08b)
RoCE = 12.92% (EBIT 2.44b / Capital Employed (Equity 6.08b + L.T.Debt 12.79b))
RoIC = 10.59% (NOPAT 2.19b / Invested Capital 20.69b)
WACC = 7.01% (E(31.93b)/V(48.10b) * Re(10.02%) + D(16.17b)/V(48.10b) * Rd(1.19%) * (1-Tc(0.10)))
Discount Rate = 10.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.28%
[DCF Debug] Terminal Value 82.40% ; FCFF base≈1.98b ; Y1≈2.07b ; Y5≈2.40b
Fair Price DCF = 222.4 (EV 51.92b - Net Debt 14.19b = Equity 37.73b / Shares 169.6m; r=7.01% [WACC]; 5y FCF grow 4.84% → 2.90% )
EPS Correlation: -11.40 | EPS CAGR: 9.07% | SUE: 0.10 | # QB: 0
Revenue Correlation: 88.66 | Revenue CAGR: 5.92% | SUE: 1.44 | # QB: 3
EPS next Quarter (2026-03-31): EPS=2.83 | Chg30d=-0.123 | Revisions Net=+1 | Analysts=14
EPS current Year (2026-12-31): EPS=12.69 | Chg30d=-0.256 | Revisions Net=+0 | Growth EPS=+6.4% | Growth Revenue=+5.5%
EPS next Year (2027-12-31): EPS=14.13 | Chg30d=-0.186 | Revisions Net=-2 | Growth EPS=+11.4% | Growth Revenue=+5.9%